{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:40:35Z","timestamp":1785390035430,"version":"3.55.0"},"reference-count":80,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009381","name":"International Medical University","doi-asserted-by":"publisher","award":["BMS I\u20102022 (15)"],"award-info":[{"award-number":["BMS I\u20102022 (15)"]}],"id":[{"id":"10.13039\/501100009381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This review aimed to synthesise the evidence related to the incidence of serious and non\u2010serious adverse events with the use of monoclonal antibodies (mAbs) among COVID\u201019 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID\u201019 regardless of disease severity. Study screening, data extraction and data analysis were performed independently by two reviewers. The Cochrane risk of bias 1.0 tool was used for methodological quality assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen studies were identified for analysis with 9682 participants in the intervention arm and 10\u2009115 participants in the control arm. Seven trials reported hepatoxicity and there was a statistically significant increase in the chance of hepatoxicity among patients treated with mAbs compared to those given standard of care (SoC) or placebo with risk ratio (RR)\u2009=\u20091.70, 95% confidence interval (CI) 1.29\u20132.24. Five trials reported for neutropenia and there was a statistically significant association of neutropenia with the use of mAbs compared to SoC or placebo with RR\u2009=\u20094.03, 95% CI 1.74\u20139.34. Ten trials reported any disease\u2010related serious adverse events related to the disease and there was a reduction of risk compared to SoC\/placebo, \u00a0although this reduction was not statistically significant (RR\u2009=\u20090.88, 95% CI 0.70\u20131.11).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of mAbs was found to be associated with an increased risk of hepatoxicity and neutropenia compared to SoC\/placebo among COVID\u201019 patients with moderate certainty of evidence. Long\u2010term observational studies are recommended to observe post\u2010COVID adverse events related to the use of mAbs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70025","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T02:51:32Z","timestamp":1741575092000},"page":"1306-1321","source":"Crossref","is-referenced-by-count":2,"title":["Adverse events associated with monoclonal antibodies used for treatment of COVID\u201019: A systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-8629","authenticated-orcid":false,"given":"Htet","family":"Htet","sequence":"first","affiliation":[{"name":"School of Medicine IMU University  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8428-6177","authenticated-orcid":false,"given":"Han You","family":"Kyung","sequence":"additional","affiliation":[{"name":"School of Medicine IMU University  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0326-424X","authenticated-orcid":false,"given":"Ismail Abdul Sattar","family":"Burud","sequence":"additional","affiliation":[{"name":"School of Medicine IMU University  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9948-4428","authenticated-orcid":false,"given":"Heethal","family":"Jaiprakash","sequence":"additional","affiliation":[{"name":"School of Medicine IMU University  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7073-8092","authenticated-orcid":false,"given":"Thiruselvi","family":"Subramaniam","sequence":"additional","affiliation":[{"name":"School of Medicine IMU University  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2852-8486","authenticated-orcid":false,"given":"Igor","family":"Iezhitsa","sequence":"additional","affiliation":[{"name":"School of Medicine IMU University  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-7449","authenticated-orcid":false,"given":"Renu","family":"Agarwal","sequence":"additional","affiliation":[{"name":"School of Medicine IMU University  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"1","key":"e_1_2_10_2_1","first-page":"20","article-title":"COVID\u201019 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management","volume":"29","author":"Ochani R","year":"2021","journal-title":"Infez Med"},{"key":"e_1_2_10_3_1","unstructured":"COVID\u201019 cases| WHO COVID\u201019 dashboard. datadot.https:\/\/covid19.who.int\/?gclid=Cj0KCQjwub\u2010HBhCyARIsAPctr7wt4KGje6JUmyWQljSMQWGhr8jvXTZSdsSZR5ay9OAp2p1uOWMFJb0aAmAXEALw_wcB. Published March 3 2024. Accessed March 23 2024."},{"key":"e_1_2_10_4_1","unstructured":"Therapeutics and COVID\u201019.www.who.int.https:\/\/www.who.int\/teams\/health-care-readiness\/covid-19\/therapeutics. Accessed March 23 2024."},{"key":"e_1_2_10_5_1","unstructured":"Clinical management of COVID\u201019: living guideline 18 August 2023. www.who.int World Health Organization 13 Jan. 2023 www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2023.2. Accessed March 13 2024."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001620\u2010z"},{"key":"e_1_2_10_7_1","unstructured":"COVID\u201019 Treatment Guidelines Panel.Coronavirus disease 2019 (COVID\u201019) treatment guidelines. National Institutes of Health.https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed August 4 2024."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010022\u201001690\u20107"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010022\u201007896\u20100"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.973246"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78697-1"},{"issue":"4","key":"e_1_2_10_13_1","first-page":"102","article-title":"Mechanism and adverse effects of COVID\u201019 drugs: a basic review","volume":"13","author":"Zadeh MN","year":"2021","journal-title":"Int J Physiol Pathophys Pharmacol"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010021\u201003270\u20102"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18179149"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010\u2010023\u201002047\u20102"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2627"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40249\u2010021\u201000857\u2010w"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_20_1","unstructured":"HtetH KyungHY IezhitsaI et al.A systematic review and meta\u2010analysis of adverse events of WHO\u2010approved COVID\u201019 treatment regimens. PROSPERO 2023 CRD42023447055.https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42023447055"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","unstructured":"HtetH KyungHY AgarwalR LezhitsaIN JaiprakashH BurudIAS.A systematic review and meta\u2010analysis of adverse events of WHO\u2010approved COVID\u201019 treatment regimens. INPLASY Registration number: (2023) INPLASY202380026. doi:10.37766\/inplasy2023.8.0026.","DOI":"10.37766\/inplasy2023.8.0026"},{"key":"e_1_2_10_22_1","volume-title":"Covidence systematic review software"},{"key":"e_1_2_10_23_1","unstructured":"International Council for Harmonisation.Clinical safety data management: definitions and standards for expedited reporting E2A. In the International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use 1994 Oct."},{"key":"e_1_2_10_24_1","unstructured":"The Cochrane Collaboration.Review Manager (RevMan) (v 2020).www.revman.cochrane.org"},{"key":"e_1_2_10_25_1","volume-title":"GRADEpro GDT: gradepro guideline development tool [software]","author":"McMaster University and Evidence Prime","year":"2024"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16180"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16181"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16179"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16176"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028836"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6820"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20102600(21)00099\u20130"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00676\u20130"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028700"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030340"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6615"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20102600(21)00081\u20133"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n84"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110825"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)00163\u20135"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2021.07.025"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.2832"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac320"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.10.015"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.005"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238\u2010020\u201000671\u2010y"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev\u2010med\u2010042420\u2010113838"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12929\u2010021\u201000784\u2010w"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18179149"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26016"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.05.021"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14516"},{"key":"e_1_2_10_54_1","volume-title":"Tocilizumab [internet]. PubMed","author":"National Library of Medicine","year":"2012"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105510"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12799"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.03.931766"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820959183"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/aas.13795"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063\u2010021\u201005963\u20106"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623312467400"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269368"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026\u2010014\u20108590\u20104"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165\u2010010\u20100279\u20105"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/aas.13795"},{"issue":"9","key":"e_1_2_10_66_1","article-title":"Retrospective analysis of tocilizumab\u2010induced neutropenia in patients with rheumatoid arthritis [abstract]","volume":"74","author":"Kim Y","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq343"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102013\u2013203559"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0314"},{"key":"e_1_2_10_70_1","unstructured":"Actemra (tocilizumab)\u2014risk of fatal anaphylaxis\u2014for health professionals: health Canada endorsed important safety information on Actemra (tocilizumab).http:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2010\/14586a-eng.php"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102016\u2013210297"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu181"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151092"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102014\u2013206695"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN109971"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59091517"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2268213"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.20.22274090"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.10.036"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203834"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.05.005"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:36:35Z","timestamp":1764740195000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/bcp.70025"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70025","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}